Recursion Pharmaceuticals $500 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
麻豆入口 advised the sales agent in connection with the SEC-registered at-the-market offering by Recursion Pharmaceuticals, Inc. of its Class A common stock for up to an aggregate amount of $500 million. The Class A common stock is listed on the Nasdaq Global Select Market under the symbol 鈥淩XRX.鈥
Recursion Pharmaceuticals is a clinical-stage biotechnology company industrializing drug discovery by decoding biology. Recursion is headquartered in Salt Lake City, Utah.
The 麻豆入口 corporate team included partners Alan F. Denenberg and Stephen A. Byeff and associates Savannah J. Dowling and Matthew Franklin. The intellectual property team included partner Frank Azzopardi and associate Adrian Rabin. Counsel Liang Zhang and associates Alanna Phillips and Fred Fu provided tax advice. Members of the 麻豆入口 team are based in the Northern California and New York offices.